Grant: Discovery Launch Supplement
University of Toronto
$12,500.00
Methods for fine-mapping causal genes, variants and cell types underlying genome-wide association study associations
EF 2024-25
Résumé
Genome-wide association studies (GWAS) associate genetic variants with complex traits. Since the first GWAS in 2005, GWAS have uncovered over 50,000 genetic associations ("hits") with human complex traits.
Unfortunately, GWAS often fail to pinpoint underlying causal variants and genes. Nearby variants are often co-inherited, so it is often unclear whether GWAS hits are causal or merely correlated with a causal variant nearby. Moreover, most GWAS hits lie outside protein-coding regions, and functional genomics strategies like expression quantitative trait locus (QTL)-based methods have trouble reliably inferring causal genes. Even when the causal gene and variant are known, it is still often unclear which of the body's myriad cell types the variant and gene act through to influence complex traits. These interpretability gaps have hindered both biological understanding and therapeutic translation.
We propose to develop statistical and machine learning models that can effectively infer ("fine-map") the causal gene(s), variant(s), and cell type(s) underlying each GWAS hit. We will sidestep the limitations of functional genomics by leveraging gene-level functional knowledge like biological networks: curated pathway databases, co-essentiality networks, protein-protein interaction networks, genetic interaction maps, and tissue- and cell type-specific co-expression networks. We plan to develop improved methods to both infer networks and integrate them with GWAS to fine-map causal genes. We will benchmark the performance of these methods on `gold-standard' causal genes, like genes with rare-variant associations for the same trait.
Functional genomics data remains valuable for identifying causal variants and cell types. Variant and cell-type prioritization are usually treated as separate problems but are intrinsically related. Different causal variants from the same GWAS may act through different cell types, so functional genomics data from just one cell type risks prioritizing the wrong causal variants for some loci. We will develop a Bayesian model to simultaneously infer which variant(s) are causal for each GWAS hit and which cell type(s) they act through, by leveraging colocalization between GWAS hits and cell type-specific chromatin accessibility QTLs across multiple cell types. We plan to collaborate with experimental geneticists to validate these predictions for loci of particular interest, by using base or prime editing to insert the candidate causal variant into cells of the candidate causal cell type and assaying for trait-relevant phenotypic changes.
In summary, our approach involves data-driven modeling to infer key biology from GWAS: the causal variant(s) driving each GWAS hit, and the gene(s) and cell type(s) they act through. Our work has applications to both basic biology, providing specific hypotheses for follow-up experimental dissection, and drug discovery, providing causal genes and mechanisms amenable to therapeutic modulation.
Programme
Discovery Launch Supplement
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
DGECR-2024-00184
Name nom
Wainberg, Michael
Department département
Lunenfeld-Tanenbaum Research Institute
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
12500
Program id
DGECR
Program name en
Discovery Launch Supplement
Program name fr
Supplément Tremplin vers la découverte
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5004
Research subject group en
Genetics
Research subject group fr
Génétique
Research subject en
Genome analysis
Research subject fr
Analyse du génome
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Methods for fine-mapping causal genes, variants and cell types underlying genome-wide association study associations
Keywords
genetic association studies; genome-wide association studies; fine-mapping; causal variants and genes; network biology; machine learning; quantitative trait loci; single-cell; chromatin accessibility; bayesian modelling
Application summary
Genome-wide association studies (GWAS) associate genetic variants with complex traits. Since the first GWAS in 2005, GWAS have uncovered over 50,000 genetic associations ("hits") with human complex traits.
Unfortunately, GWAS often fail to pinpoint underlying causal variants and genes. Nearby variants are often co-inherited, so it is often unclear whether GWAS hits are causal or merely correlated with a causal variant nearby. Moreover, most GWAS hits lie outside protein-coding regions, and functional genomics strategies like expression quantitative trait locus (QTL)-based methods have trouble reliably inferring causal genes. Even when the causal gene and variant are known, it is still often unclear which of the body's myriad cell types the variant and gene act through to influence complex traits. These interpretability gaps have hindered both biological understanding and therapeutic translation.
We propose to develop statistical and machine learning models that can effectively infer ("fine-map") the causal gene(s), variant(s), and cell type(s) underlying each GWAS hit. We will sidestep the limitations of functional genomics by leveraging gene-level functional knowledge like biological networks: curated pathway databases, co-essentiality networks, protein-protein interaction networks, genetic interaction maps, and tissue- and cell type-specific co-expression networks. We plan to develop improved methods to both infer networks and integrate them with GWAS to fine-map causal genes. We will benchmark the performance of these methods on `gold-standard' causal genes, like genes with rare-variant associations for the same trait.
Functional genomics data remains valuable for identifying causal variants and cell types. Variant and cell-type prioritization are usually treated as separate problems but are intrinsically related. Different causal variants from the same GWAS may act through different cell types, so functional genomics data from just one cell type risks prioritizing the wrong causal variants for some loci. We will develop a Bayesian model to simultaneously infer which variant(s) are causal for each GWAS hit and which cell type(s) they act through, by leveraging colocalization between GWAS hits and cell type-specific chromatin accessibility QTLs across multiple cell types. We plan to collaborate with experimental geneticists to validate these predictions for loci of particular interest, by using base or prime editing to insert the candidate causal variant into cells of the candidate causal cell type and assaying for trait-relevant phenotypic changes.
In summary, our approach involves data-driven modeling to infer key biology from GWAS: the causal variant(s) driving each GWAS hit, and the gene(s) and cell type(s) they act through. Our work has applications to both basic biology, providing specific hypotheses for follow-up experimental dissection, and drug discovery, providing causal genes and mechanisms amenable to therapeutic modulation.